Stock listing
NASDAQ:RVPH Reviva Pharmaceuticals Holdings, Inc. Stock
Home listing (NASDAQ) of Reviva Pharmaceuticals Holdings, Inc.
Follow Reviva Pharmaceuticals Holdings, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:RVPH
$0.281 USD -0.019 (-6.3%)
Close on Nov 20, 2026
- Day range
- $0.281 – $0.335 USDNov 20, 2026
- Volume
- 5,455 sharesNov 20, 2026
- Market cap
- $3.68M USDAt the close on Nov 20, 2026 · price × 13.11M shares outstanding
- 52-week range
- $0.262 – $15.400 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $11,896 USDMedian day 19,291 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:RVPH · Home | $0.281 USD | -0.019 (-6.3%) | 5,455 | $0.291 | $0.335 | $0.281 | $0.300 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:RVPH · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.281 | -0.019 | -6.3% | $0.291 | $0.335 | $0.281 | 5,455 | |
| $0.300 | -0.007 | -2.1% | $0.280 | $0.390 | $0.280 | 2,330 | |
| $0.307 | +0.007 | +2.2% | $0.300 | $0.307 | $0.300 | 1,215 | |
| $0.300 | -0.040 | -11.8% | $0.340 | $0.363 | $0.280 | 19,887 | |
| $0.340 | +0.000 | 0.0% | $0.340 | $0.420 | $0.340 | 7,016 | |
| $0.340 | 0.000 | 0.0% | $0.340 | $0.340 | $0.340 | 498 | |
| $0.340 | -0.035 | -9.4% | $0.354 | $0.420 | $0.338 | 10,503 | |
| $0.375 | +0.055 | +17.3% | $0.330 | $0.417 | $0.330 | 4,079 | |
| $0.320 | -0.048 | -12.9% | $0.370 | $0.417 | $0.319 | 13,226 | |
| $0.368 | +0.028 | +8.1% | $0.340 | $0.370 | $0.319 | 47,980 | |
| $0.340 | -0.040 | -10.5% | $0.350 | $0.400 | $0.315 | 30,864 | |
| $0.380 | -0.021 | -5.2% | $0.374 | $0.466 | $0.310 | 45,722 | |
| $0.401 | -0.028 | -6.5% | $0.416 | $0.434 | $0.374 | 19,322 | |
| $0.429 | +0.079 | +22.6% | $0.350 | $0.451 | $0.312 | 54,452 | |
| $0.350 | -0.042 | -10.6% | $0.400 | $0.403 | $0.314 | 110,080 | |
| $0.392 | -0.023 | -5.7% | $0.390 | $0.460 | $0.390 | 9,742 | |
| $0.415 | -0.035 | -7.8% | $0.440 | $0.450 | $0.403 | 23,255 | |
| $0.450 | +0.024 | +5.7% | $0.420 | $0.480 | $0.410 | 11,444 | |
| $0.426 | -0.022 | -5.0% | $0.433 | $0.500 | $0.411 | 39,612 | |
| $0.448 | -0.027 | -5.7% | $0.405 | $0.500 | $0.405 | 13,017 | |
| $0.475 | +0.031 | +7.0% | $0.480 | $0.480 | $0.431 | 28,875 | |
| $0.444 | -0.016 | -3.5% | $0.430 | $0.500 | $0.430 | 27,458 | |
| $0.460 | +0.010 | +2.2% | $0.443 | $0.500 | $0.385 | 32,423 | |
| $0.450 | -0.020 | -4.4% | $0.470 | $0.500 | $0.450 | 33,977 | |
| $0.471 | -0.005 | -0.9% | $0.495 | $0.512 | $0.450 | 38,463 | |
| $0.475 | -0.003 | -0.7% | $0.485 | $0.530 | $0.470 | 94,660 | |
| $0.478 | -0.017 | -3.5% | $0.461 | $0.485 | $0.461 | 23,544 | |
| $0.495 | +0.005 | +1.1% | $0.510 | $0.510 | $0.461 | 15,234 | |
| $0.490 | -0.010 | -2.0% | $0.480 | $0.500 | $0.441 | 17,554 | |
| $0.500 | +0.005 | +1.0% | $0.480 | $0.500 | $0.480 | 11,914 | |
| $0.495 | -0.005 | -1.0% | $0.500 | $0.530 | $0.495 | 21,108 | |
| $0.500 | -0.011 | -2.2% | $0.500 | $0.530 | $0.500 | 57,246 | |
| $0.511 | +0.001 | +0.2% | $0.500 | $0.540 | $0.500 | 19,259 | |
| $0.510 | +0.010 | +2.0% | $0.478 | $0.520 | $0.470 | 42,354 | |
| $0.500 | 0.000 | 0.0% | $0.470 | $0.510 | $0.470 | 59,250 | |
| $0.500 | +0.030 | +6.4% | $0.480 | $0.500 | $0.470 | 9,953 | |
| $0.470 | -0.007 | -1.5% | $0.470 | $0.504 | $0.470 | 12,236 | |
| $0.477 | -0.001 | -0.2% | $0.490 | $0.520 | $0.470 | 59,648 | |
| $0.478 | -0.002 | -0.4% | $0.480 | $0.528 | $0.478 | 14,468 | |
| $0.480 | -0.040 | -7.7% | $0.478 | $0.500 | $0.478 | 7,317 | |
| $0.520 | +0.040 | +8.3% | $0.500 | $0.528 | $0.480 | 6,570 | |
| $0.480 | -0.048 | -9.1% | $0.494 | $0.520 | $0.480 | 7,181 | |
| $0.528 | +0.028 | +5.6% | $0.490 | $0.528 | $0.470 | 10,000 | |
| $0.500 | +0.020 | +4.2% | $0.480 | $0.529 | $0.478 | 18,998 | |
| $0.480 | -0.022 | -4.4% | $0.480 | $0.529 | $0.480 | 30,390 | |
| $0.502 | +0.012 | +2.5% | $0.490 | $0.529 | $0.490 | 10,013 | |
| $0.490 | +0.010 | +2.1% | $0.500 | $0.529 | $0.480 | 9,991 | |
| $0.480 | 0.000 | 0.0% | $0.480 | $0.530 | $0.480 | 28,430 | |
| $0.480 | -0.055 | -10.3% | $0.535 | $0.535 | $0.470 | 18,797 | |
| $0.535 | +0.035 | +7.0% | $0.500 | $0.535 | $0.500 | 50,655 | |
| $0.500 | -0.032 | -6.1% | $0.555 | $0.555 | $0.500 | 12,174 | |
| $0.533 | -0.006 | -1.1% | $0.500 | $0.555 | $0.490 | 35,084 | |
| $0.539 | +0.008 | +1.6% | $0.510 | $0.555 | $0.500 | 12,144 | |
| $0.530 | 0.000 | 0.0% | $0.510 | $0.555 | $0.500 | 1,893 | |
| $0.530 | -0.010 | -1.9% | $0.530 | $0.555 | $0.510 | 23,593 | |
| $0.540 | +0.005 | +0.9% | $0.550 | $0.555 | $0.490 | 31,709 | |
| $0.535 | +0.025 | +4.9% | $0.490 | $0.535 | $0.480 | 39,542 | |
| $0.510 | +0.030 | +6.3% | $0.480 | $0.520 | $0.470 | 18,184 | |
| $0.480 | -0.038 | -7.4% | $0.530 | $0.530 | $0.470 | 39,768 | |
| $0.519 | +0.014 | +2.8% | $0.500 | $0.520 | $0.500 | 13,897 | |
| $0.505 | -0.001 | -0.1% | $0.480 | $0.515 | $0.470 | 17,592 | |
| $0.505 | +0.010 | +2.1% | $0.460 | $0.520 | $0.450 | 67,042 | |
| $0.495 | +0.016 | +3.4% | $0.500 | $0.510 | $0.460 | 7,298 | |
| $0.479 | -0.005 | -0.9% | $0.482 | $0.510 | $0.460 | 34,494 | |
| $0.483 | -0.007 | -1.4% | $0.530 | $0.530 | $0.480 | 27,477 | |
| $0.490 | -0.010 | -2.0% | $0.518 | $0.535 | $0.460 | 31,077 |
Splits
1 split · NASDAQ:RVPH · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-20 | Consolidation |
- Ticker
- NASDAQ:RVPH
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Jun 23, 2026
Reviva Pharmaceuticals to Present at the Life Sciences Investor Forum on June 24th
Latest news
Reviva Pharmaceuticals to Present at the Life Sciences Investor Forum on June 24th
Jun 23, 2026
Closed $0.695 (-0.4%) on Jun 23, 2026
Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights
May 13, 2026
Closed $0.352 (-55.7%) on May 13, 2026
Reviva to Participate in a Fireside Chat Hosted by A.G.P. on Brilaroxazine’s Potential Across Multiple Neuropsychiatric Indications
Apr 23, 2026
Closed $0.89 (-4.3%) on Apr 23, 2026
Reviva Announces Letter to Shareholders
Apr 15, 2026
Closed $0.89 (+3.5%) on Apr 15, 2026
Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights
Mar 30, 2026
Closed $0.66 (-11.0%) on Mar 30, 2026
Reviva Pharmaceuticals Holdings, Inc. Announces Closing of $10 Million Public Offering
Mar 23, 2026
Closed $0.893 (+11.6%) on Mar 23, 2026
Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial of Brilaroxazine to Treat Negative Symptoms in Schizophrenia
Jan 8, 2026
Closed $7.32 (+5.7%) on Jan 8, 2026
Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum
Dec 29, 2025
Closed $5.80 (-5.4%) on Dec 29, 2025
Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia
Dec 23, 2025
Closed $6.43 (-45.5%) on Dec 23, 2025
Reviva Pharmaceuticals Holdings, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 9 in the last 12 months · 92 in all · newest Jun 23, 2026 · oldest 2021
- Decks
- 5 decks · latest Jun 2, 2025
Where Reviva Pharmaceuticals Holdings, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:RVPH · Home listing · This page | NASDAQ | United States | USD |
| BOATS:RVPH | BOATS | United States | USD |
Valuation
Price/book 0.3× against a median of 0.9×: 2nd lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$13.77M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 0.3×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.57
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Reviva Pharmaceuticals Holdings, Inc. · NASDAQ:RVPH | US$3.68M | −US$13.77M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 1.57 |
| AdAlta Ltd. · ASX:1AD | US$4.25M | US$3.40M | n/a | n/a | n/a | 17.4× | n/a | 0.0× | n/a |
| Percheron Therapeutics Limited · ASX:PER | US$3.94M | US$1.27M | n/a | n/a | n/a | 0.8× | n/a | 0.0× | n/a |
| Lantern Pharma Inc. · NASDAQ:LTRN | US$3.89M | −US$3.69M | n/a | n/a | n/a | 2.8× | n/a | 0.0× | 2.80 |
| Silo Pharma, Inc. · NASDAQ:SILO | US$3.77M | −US$4.28M | n/a | n/a | n/a | 0.5× | n/a | 0.0× | 1.23 |
| Alzamend Neuro, Inc. · NASDAQ:ALZN | US$3.74M | −US$3.85M | n/a | n/a | n/a | 0.7× | n/a | 0.0× | 2.00 |
| Biotron Limited · ASX:BIT | US$3.69M | US$2.66M | n/a | n/a | n/a | 1.9× | n/a | 0.0× | n/a |
| Liminatus Pharma, Inc. · NASDAQ:LIMN | US$3.37M | US$1.80M | n/a | n/a | n/a | 11.2× | n/a | 4.8× | 0.94 |
| Xenetic Biosciences, Inc. · NASDAQ:XBIO | US$3.28M | −US$2.53M | n/a | −0.8× | n/a | 0.7× | −123.7% | 0.0× | 1.46 |
| Aprea Therapeutics, Inc. · NASDAQ:APRE | US$3.25M | −US$34.60M | n/a | n/a | n/a | 0.1× | n/a | 0.0× | 0.73 |
| Spago Nanomedical AB · OMXSTO:SPAGO | US$3.20M | US$22,063 | n/a | 5.6× | n/a | 1.0× | n/a | 0.0× | n/a |
| Median of the others | US$3.72M | −US$1.25M | 2.4× | 0.9× | −123.7% | 0.0× | 1.35 |
Forecasts
3 strong buy · 3 buy · Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.
- Price target
- 17.50 USD · Analysts' mean
- EPS, year to Dec 2026
- -0.85 · 1 analyst
Team and board
| Officer | Role |
|---|---|
| Bruce Mackle | Investor Relations |
| PJ Kelleher | Investor Relations |
| Greg Young | VP Corporate Services |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 13, 2026 | −11.8% |
| Q2 2026 | Aug 13, 2026 · After close | +1.1% |
| Q1 2026 | May 13, 2026 · After close | +10.8% |
| Q4 2025 | Mar 23, 2026 | +3.4% |
| Q3 2025 | Nov 13, 2025 · After close | −7.2% |
| Q2 2025 | Aug 14, 2025 · After close | +15.8% |
| Q1 2025 | May 15, 2025 · After close | −2.3% |
| Q4 2024 | Mar 31, 2025 | −38.5% |
| Q3 2024 | Nov 14, 2024 · After close | −7.0% |
| Q2 2024 | Aug 14, 2024 · Before open | +4.2% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 14, 2024 · Before open | +7.3% |
| Q4 2023 | Mar 19, 2024 · After close | −1.4% |
| Q3 2023 | Nov 14, 2023 · After close | −8.8% |
| Q2 2023 | Aug 14, 2023 · After close | +2.4% |
| Q1 2023 | May 15, 2023 · After close | −3.1% |
| Q4 2022 | Mar 30, 2023 · Before open | −10.1% |
| Q3 2022 | Nov 14, 2022 · After close | −20.4% |
| Q2 2022 | Aug 15, 2022 · After close | −11.6% |
| Q1 2022 | May 16, 2022 · After close | +8.0% |
| Q4 2021 | Mar 15, 2022 · After close | +4.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Technical Presentation (June 2025) | Technical | 41 slides | Jun 2, 2025 |
| Investor Presentation (March 2021) | Investor deck | 23 slides | Mar 4, 2021 |
| Tenzing Acquisition — SPAC Merger (November 2020) | SPAC merger | 29 slides | Nov 6, 2020 |
| Tenzing Acquisition — SPAC Merger (October 2020) | SPAC merger | 28 slides | Oct 6, 2020 |
| SPAC Merger (July 2020) | SPAC merger | 28 slides | Jul 29, 2020 |
Financings
| Raise | Date |
|---|---|
| Public offering of shares of common stock (or common stock equivalents) with Series E and Series F warrants Update: about US$9M · US$0.335 a share · Warrants at US$0.335 · A.G.P./Alliance Global Partners Dealers: A.G.P./Alliance Global Partners (lead) Use of proceeds: Research and development activities, working capital and other general corporate purposes | Sep 19, 2025 |
| Public offering of public equity offering Closed: US$10M raised · US$0.5 a share · Warrants at US$0.5 · A.G.P./Alliance Global Partners Dealers: A.G.P./Alliance Global Partners (lead) Use of proceeds: Research and development activities, working capital and other general corporate purposes | Aug 14, 2025 |
| Public offering of shares of common stock (or common share equivalents) and warrants Announced: about US$18M · US$1.5 a share · Warrants at US$1.5 · Citizens JMP +1 Dealers: Citizens JMP (lead), Citizens JMP Securities, LLC (lead) Use of proceeds: Fund research and development activities and for working capital and other general corporate purposes | Dec 16, 2024 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Went public as Tenzing Acquisition Corp., a blank check company (SPAC). Priced at US$10.00 a unit on Aug 20, 2018.
- Price
- US$10.00 a unit
- Units offered
- 5,500,000 units
- Offering size
- US$55 million
- Underwriters' option
- Up to 825,000 more units
- Listing
- TZACU on the Nasdaq Capital Market
- Underwriter
- Maxim Group LLC
- Units delivered
- On or about Aug 23, 2018
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jun 19, 2018 |
| Filed publicly | Jul 20, 2018 |
| Amended twice | Newest Aug 16, 2018 |
| Shares registered with an exchange | Aug 20, 2018 |
| Declared effective by the SEC | Aug 20, 2018 |
| Final prospectus, with the price | Aug 22, 2018 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Aug 22, 2018 |
| EFFECT · Notice that a registration is effective | Aug 20, 2018 |
| S-1MEF · Registration of more shares for the same offering | Aug 20, 2018 |
| CORRESP · Letter to the SEC | Aug 20, 2018 |
| CORRESP · Letter to the SEC | Aug 20, 2018 |
| CERT · Exchange's certificate of listing | Aug 20, 2018 |
| 8-A12B · Registration of shares for listing on an exchange | Aug 20, 2018 |
| S-1/A · Registration statement, amended | Aug 16, 2018 |
| S-1/A · Registration statement, amended | Aug 6, 2018 |
| S-1 · Registration statement | Jul 20, 2018 |
All 13 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Jul 20, 2018 |
| UPLOAD · Letter from the SEC | Jul 16, 2018 |
| DRS · Draft registration statement | Jun 19, 2018 |
Open IPO · From the cover of the final prospectus (424B4) filed Aug 22, 2018
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Research and development | 11.7M | 22.9M | 31.4M | 22.9M | 4.85M | 295.1K | 195.7K | |
| Operating income | -20.2M | -30.8M | -39.5M | -28.2M | -10.1M | -2.43M | -724.7K | -376.9K |
| Depreciation and amortization | 0 | 591 | 645 | |||||
| EBITDA | -10.1M | -2.43M | -376.2K | |||||
| Interest expense | 13.4K | 18.5K | 33.7K | 1.45M | 469.4K | |||
| Income before tax | -19.8M | -29.9M | -39.2M | -28.2M | -8.52M | -3.78M | -846.0K | |
| Income tax | 18.9K | 19.5K | 16.9K | 20.8K | 6.00K | 800 | 0 | 800 |
| Net income | -19.9M | -29.9M | -39.3M | -28.3M | -8.52M | -3.78M | 617.9K | -846.8K |
| Earnings per share, basic | -5.48 | -17.73 | -1.65 | -1.45 | -0.58 | -1.24 | -0.21 | -0.31 |
| Earnings per share, diluted | -1.24 | -0.21 | -0.31 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 14.4M | 13.5M | 23.4M | 18.5M | 29.7M | 8.76M | 69.3K | 193 |
| Current assets | 15.1M | 14.7M | 23.7M | 138.9K | ||||
| Property, plant and equipment | 0 | 591 | ||||||
| Total assets | 15.9M | 15.5M | 23.7M | 18.9M | 31.4M | 8.76M | 61.0M | 2.60K |
| Accounts payable | 3.01M | 6.28M | 3.85M | 3.52M | 509.6K | 1.01M | 299.7K | 224.5K |
| Current liabilities | 7.28M | 14.6M | 17.2M | 9.96M | 2.34M | 1.33M | 299.7K | |
| Total liabilities | 7.28M | 14.7M | 18.0M | 10.5M | 2.72M | 3.30M | 3.26M | 6.81M |
| Shareholders' equity | 8.65M | 812.6K | 5.72M | 8.39M | 28.7M | 5.47M | 5.00M | -6.81M |
| Shares outstanding | 5.87M | 2.36M | 27.9M | 20.4M | 14.4M | 9.23M | 2.70M | 15.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -24.6M | -33.5M | -28.3M | -19.0M | -10.7M | -4.07M | -426.6K | -218.4K |
| Cash from investing | 5.70M | |||||||
| Cash from financing | 25.6M | 23.7M | 33.2M | 7.79M | 31.6M | 12.8M | -5.52M | 100.0K |
| Change in cash | 962.5K | -9.89M | 4.85M | -11.2M | 20.9M | 8.76M | -243.8K | -118.4K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Nov 9, 2026 | Annual report | SEC |
| DEF 14A · Proxy statement | Nov 9, 2026 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Oct 29, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 3, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 31, 2026 | Big-stake notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 25-NSE | Jul 10, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | May 14, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2026 | Results | SEC |
| 8-K · Current report | May 13, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | May 7, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Apr 15, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 30, 2026 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Mar 30, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 30, 2026 | Results | SEC |
| 10-K · Annual report | Mar 27, 2026 | Annual report | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 25, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 24, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 19, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Mar 19, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Mar 18, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 5, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 23, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 16, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Dec 23, 2025 | Meeting outcome | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 22, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 25-NSE | Dec 12, 2025 | Other filings | SEC |
| DEFA14A · Additional proxy material | Dec 5, 2025 | Meeting notice | SEC |
| 8-K · Current report | Nov 13, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 13, 2025 | Quarterly report | SEC |
| ARS · Annual report to shareholders | Nov 4, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Nov 4, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Nov 4, 2025 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Oct 24, 2025 | Meeting notice | SEC |
| 8-K · Current report | Oct 17, 2025 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Sep 29, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Sep 26, 2025 | Current report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 24, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Sep 24, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Sep 19, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Sep 19, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Sep 18, 2025 | Offer document | SEC |
| 8-K · Current report | Aug 14, 2025 | Results | SEC |
| 10-Q · Quarterly report | Aug 14, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 1, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jul 1, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 1, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jun 26, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Jun 26, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Jun 25, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 6, 2025 | Current report | SEC |
| 8-K · Current report | Jun 2, 2025 | Current report | SEC |
| 424B5 · Prospectus | May 30, 2025 | Offer document | SEC |
| 8-K · Current report | May 30, 2025 | Material contract | SEC |
| 10-Q · Quarterly report | May 15, 2025 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 8-K · Current report | May 15, 2025 | Results | SEC |
| S-8 · Registration statement for employee plans | Apr 3, 2025 | Offer document | SEC |
| 10-K · Annual report | Apr 2, 2025 | Annual report | SEC |
| NT 10-K · Late filing notice | Mar 31, 2025 | Explanation request | SEC |
| 8-K · Current report | Mar 31, 2025 | Results | SEC |
| 8-K · Current report | Feb 18, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 18, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 7, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 31, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 23, 2024 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Dec 20, 2024 | Big-stake notice | SEC |
| 424B5 · Prospectus | Dec 18, 2024 | Offer document | SEC |
| 8-K · Current report | Dec 17, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Dec 16, 2024 | Offer document | SEC |
| 8-K · Current report | Dec 16, 2024 | Current report | SEC |
| 8-K · Current report | Dec 12, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | Dec 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 12, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 14, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 14, 2024 | Quarterly report | SEC |
| SC 13G · Big-stake notice | Nov 14, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 12, 2024 | Current report | SEC |
| ARS · Annual report to shareholders | Oct 28, 2024 | Annual report | SEC |
| DEF 14A · Proxy statement | Oct 28, 2024 | Meeting notice | SEC |
| PRE 14A · Preliminary proxy statement | Oct 17, 2024 | Meeting notice | SEC |
| 8-K · Current report | Sep 17, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Sep 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 17, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Aug 23, 2024 | Big-stake notice | SEC |
| SC 13D/A · Big-stake notice, amended | Aug 23, 2024 | Big-stake notice | SEC |
| 8-K/A · Current report, amended | Aug 22, 2024 | Material contract | SEC |
| UPLOAD · Letter from the SEC | Aug 22, 2024 | Other filings | SEC |
| 424B5 · Prospectus | Aug 22, 2024 | Offer document | SEC |
| 8-K · Current report | Aug 21, 2024 | Material contract | SEC |
| SC 13G · Big-stake notice | Aug 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2024 | Results | SEC |
| CORRESP · Letter to the SEC | Aug 7, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jul 24, 2024 | Other filings | SEC |
| 8-K · Current report | Jul 9, 2024 | Current report | SEC |
| SC 13D/A · Big-stake notice, amended | May 31, 2024 | Big-stake notice | SEC |
| 8-K · Current report | May 29, 2024 | Material contract | SEC |
| 424B5 · Prospectus | May 28, 2024 | Offer document | SEC |
| S-8 · Registration statement for employee plans | May 17, 2024 | Offer document | SEC |
| 8-K · Current report | May 15, 2024 | Current report | SEC |
| 10-Q · Quarterly report | May 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2024 | Results | SEC |
| 8-K · Current report | Apr 15, 2024 | Current report | SEC |
| 10-K · Annual report | Apr 15, 2024 | Annual report | SEC |
| 8-K · Current report | Apr 15, 2024 | Results | SEC |
| 8-K · Current report | Apr 15, 2024 | Results | SEC |
| NT 10-K · Late filing notice | Apr 2, 2024 | Explanation request | SEC |
| SC 13D/A · Big-stake notice, amended | Feb 16, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 14, 2024 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Feb 14, 2024 | Other filings | SEC |
| 424B4 · Prospectus | Feb 13, 2024 | Offer document | SEC |
| UPLOAD · Letter from the SEC | Feb 9, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 9, 2024 | Other filings | SEC |
| S-3 · Registration statement | Feb 2, 2024 | Offer document | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 30, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 22, 2023 | Insider trade | SEC |
| 8-K · Current report | Nov 17, 2023 | Material contract | SEC |
| 424B5 · Prospectus | Nov 17, 2023 | Offer document | SEC |
| 4 · Change in ownership | Nov 14, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2023 | Insider trade | SEC |
| 8-K · Current report | Nov 14, 2023 | Meeting outcome | SEC |
| 8-K/A · Current report, amended | Nov 14, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Nov 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2023 | Results | SEC |
| 8-K · Current report | Oct 30, 2023 | Current report | SEC |
| ARS · Annual report to shareholders | Oct 4, 2023 | Annual report | SEC |
| DEF 14A · Proxy statement | Oct 4, 2023 | Meeting notice | SEC |
| 8-K · Current report | Oct 4, 2023 | Current report | SEC |
| 8-K · Current report | Aug 17, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Aug 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2023 | Results | SEC |
| 8-K · Current report | Jul 24, 2023 | Current report | SEC |
| 8-K · Current report | Jun 23, 2023 | Current report | SEC |
| 10-Q · Quarterly report | May 15, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2023 | Results | SEC |
| SC 13D/A · Big-stake notice, amended | May 5, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 27, 2023 | Insider trade | SEC |
| 8-K · Current report | Apr 27, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Apr 27, 2023 | Insider trade | SEC |
| 424B3 · Prospectus | Apr 5, 2023 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Apr 5, 2023 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Mar 30, 2023 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Mar 30, 2023 | Offer document | SEC |
| 10-K · Annual report | Mar 30, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 30, 2023 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Jan 4, 2023 | Current report | SEC |
| 4 · Change in ownership | Nov 21, 2022 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 14, 2022 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2022 | Results | SEC |
| 4 · Change in ownership | Nov 14, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2022 | Insider trade | SEC |
| 8-K · Current report | Nov 14, 2022 | Meeting outcome | SEC |
| 4 · Change in ownership | Nov 14, 2022 | Insider trade | SEC |
| 424B4 · Prospectus | Oct 18, 2022 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Oct 18, 2022 | Other filings | SEC |
| CORRESP · Letter to the SEC | Oct 13, 2022 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Oct 12, 2022 | Other filings | SEC |
| DEF 14A · Proxy statement | Oct 11, 2022 | Meeting notice | SEC |
| S-1 · Registration statement | Oct 6, 2022 | Offer document | SEC |
| 4 · Change in ownership | Oct 3, 2022 | Insider trade | SEC |
| D | Sep 19, 2022 | Other filings | SEC |
| SC 13D/A · Big-stake notice, amended | Sep 12, 2022 | Big-stake notice | SEC |
| 4 · Change in ownership | Sep 12, 2022 | Insider trade | SEC |
| 8-K · Current report | Sep 7, 2022 | Material contract | SEC |
| 424B5 · Prospectus | Sep 7, 2022 | Offer document | SEC |
| 8-K · Current report | Aug 15, 2022 | Results | SEC |
| 10-Q · Quarterly report | Aug 15, 2022 | Quarterly report | SEC |
| 8-K · Current report | Jul 28, 2022 | Current report | SEC |
| 8-K · Current report | Jul 27, 2022 | Current report | SEC |
| 4 · Change in ownership | Jun 30, 2022 | Insider trade | SEC |
| 8-K · Current report | Jun 27, 2022 | Management or board change | SEC |
| 10-Q · Quarterly report | May 16, 2022 | Quarterly report | SEC |
| 8-K · Current report | May 16, 2022 | Results | SEC |
This page holds 200 of 417 filings. Open Filings
Cap table
Built by 6ix from Reviva Pharmaceuticals Holdings, Inc.’s releases · as of Aug 14, 2025
- Common shares
- 13,110,377
- Fully diluted
- 13,110,377
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 13,110,377 |
Warrants and options
| Lot |
|---|
| Warrants · US$0.50 · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 13,110,377 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Nina B Shapiro Other companies: Aeries Technology, Inc. (Director · Since at least Nov 6, 2023); Eucrates Biomedical Acquisition Corp. (Director · Oct 23, 2020 – Oct 23, 2020 · Past); Identiv, Inc. (Director · Jun 28, 2016 – Jun 1, 2022 · Past) | Director · Aug 20, 2018 – Aug 20, 2018 · Past |
| William I Campbell Other companies: Eucrates Biomedical Acquisition Corp. (Director · Oct 23, 2020 – Oct 23, 2020 · Past); The KeyW Holding Corporation (Director · Jul 1, 2016 – Jun 11, 2019 · Past) | Director · Aug 20, 2018 – Aug 20, 2018 · Past |
| Gonzalo Cordova Other companies: Eucrates Biomedical Acquisition Corp. (Chief Financial Officer · Oct 23, 2020 – Oct 23, 2020 · Past) | Chief Financial Officer · Aug 20, 2018 – Aug 20, 2018 · Past |
| Leslie D Funtleyder Other companies: Applied Therapeutics Inc (Chief Financial Officer, Director · Since at least Oct 1, 2020) | Director · Since at least Jun 15, 2021 |
| Parag Saxena Other companies: Eucrates Biomedical Acquisition Corp. (Chief Executive Officer, Director · Oct 23, 2020 – Nov 24, 2020 · Past) | Director · Since at least Aug 20, 2018 |
| Bruce Mackle | Investor Relations · Since at least Jun 5, 2025 |
| Greg Young | VP Corporate Services · Since at least Jun 23, 2026 |
| Laxminarayan Bhat | President and CEO, Director · Since at least Dec 14, 2020 |
| Marc Cantillon | Chief Medical Officer · Dec 14, 2020 – Dec 14, 2020 · Past |
| Narayan Prabhu | Chief Financial Officer · Since at least Mar 18, 2026 |
All 15 people
| Person | Seat |
|---|---|
| PJ Kelleher | Investor Relations · Since at least Jun 23, 2026 |
| Purav Patel | Director · Since at least Dec 14, 2020 |
| Rahul Nayar | Chief Executive Officer, Director · Aug 20, 2018 – Aug 30, 2018 · Past |
| Richard A Margolin | Director · Since at least Dec 14, 2020 |
| Vikas Thapar | Director · Aug 20, 2018 – Aug 20, 2018 · Past |
Log in to ask 6ix AI your own questions about Reviva Pharmaceuticals Holdings, Inc.